AzTrials
AzTrials

Opioid Use DisorderPhilly NavSTARNCT06634277

Philly NavSTAR Implementation Trial

A study testing NavSTAR (Philly adaptation) in people with Opioid Use Disorder, run by Friends Research Institute, Inc. at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Patient Navigation (PN) interventions following hospitalization can reduce the differences that certain groups have been trying to access opioid use disorder treatment. These differences, which affect racial minority groups the most, contribute to the opioid overdose epidemic. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Opioid Use Disorder
What is being tested?
NavSTAR (Philly adaptation)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
32 participants
Where
2 sitesUnited States
Study dates
9 Aug 2024to 31 Aug 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • age 18 or older;
  • current DSM-5 criteria for moderate to severe OUD;
  • willing and able to provide informed consent in English.

Who cannot join

  • enrollment in OUD treatment 30-days prior to hospitalization;
  • residency outside the City of Philadelphia;
  • pregnancy;
  • planned discharge to a long-term inpatient care facility (e.g., hospice);
  • hospitalization for a suicide attempt.

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Jefferson Health

    Philadelphia, Pennsylvania, 19107

  • Friends Research Institute

    Philadelphia, Pennsylvania, 19125

Other trials in United States

About this study

Official title: Implementing a Patient Navigation Intervention Across a Health System to Address Treatment Entry Inequities

Patient Navigation (PN) interventions following hospitalization can reduce the differences that certain groups have been trying to access opioid use disorder treatment. These differences, which affect racial minority groups the most, contribute to the opioid overdose epidemic. However, delivering PN interventions on a wide scale requires many resources and coordination across institutions. This will use an evidence-based process to find solutions to these significant barriers by engaging community, hospital, and patient partners. This study is being conducted to learn more about how to implement NavSTAR, a patient navigation intervention for people with opioid use disorder, across a health system. Our research team showed in a previous study with 400 participants that NavSTAR significantly increased entry into opioid use disorder treatment, reduced readmissions to the hospital, and was highly cost- effective compared to treatment as usual. This study will first pilot NavSTAR with 32 patient participants across 4 hospitals in the City of Philadelphia. Then, we will conduct a large trial with 720 patient participants to see if we can reach people who need the intervention, and create a sustainable plan to continue the intervention after the grant award period.

Read the detailed description

Opioid agonist treatment (OAT) is protective against overdose, yet less than 20% of people with opioid use disorder (OUD) engage in such treatment. Hospital utilization is high among people with OUD and can be a 'reachable moment' to initiate OAT. However, most hospitals lack the capacity to follow up with patients after discharge. Theory-based, empirically supported patient navigator (PN) interventions following hospital discharge reduce inequities in accessing community-based OAT by helping patients navigate complex systems of care. However, challenges persist in implementing PN interventions on a wide scale, as they require coordination across institutions, data sharing, dedicated personnel, and community resources. This is especially true in settings that reach diverse, resource-challenged communities. To bring these interventions to scale, strategies are needed to assess factors that influence PN implementation in hospitals to increase feasibility, reach, and sustainability. Testing innovative implementation strategies for PN interventions has the potential for significant impact, as it will demonstrate implementation success of an intervention that can address the opioid epidemic in real-world settings and close the research-to-practice translation gap. The proposed study is a type II hybrid implementation-effectiveness trial of Navigation Services To Avoid Rehospitalization (NavSTAR). Our research team showed in a single-site randomized trial with 400 participants that NavSTAR significantly increased OAT entry, reduced readmissions, and was highly cost-effective compared to treatment as usual. The present study will test an Implementation Facilitation (IF) strategy following Proctor's conceptual model using an external facilitator and an internal local clinical champion to provide training, resources, and performance feedback to implement NavSTAR in four hospitals. We hypothesize that engaging stakeholders (including patients, clinicians, and community leaders) in an IF strategy will create and test an implementation process that is feasible, acceptable, and effective in expanding access to OAT post-discharge. The R61 phase will conduct process mapping to identify existing hospital workflow and then refine an IF strategy through sequential pilot trials at 4 hospital sites in preparation for the R33 phase. The team's NavSTAR operations manual will be adapted to the sites to train the existing staff. R61 milestones include the creation of an implementation toolkit and data-sharing agreements.

The developmental R61 phase will focus on needs assessment and identifying IF strategies for system-wide adoption of NavSTAR in preparation for the R33 trial phase. This will be accomplished through four inter-related processes: 1) Process mapping with the CAB and CAP, 2) Conducting qualitative interviews to gain diverse stakeholder input, 3) Modifying the IF strategy, and 4) Conducting four short-duration, iterative pilot testing cycles in four hospitals to examine the IF strategy for feasibility and acceptability. Pilot testing will occur with existing personnel (master's level social workers) utilizing the NavSTAR manual of operations. Interviews with current participants in the pilot testing, organizational stakeholders, navigators, and clinician champions will be conducted both before and after the pilot testing cycles.

Aim 1: Providers, staff, organizational leadership, and patients at the four hospitals will be asked to participate in the study (N=40) by completing interviews about current navigation/ discharge processes and optimal IF strategies.

Aim 2: Patients will be recruited across four hospitals (8 at each hospital) to conduct a pilot trial (N=32) of NavSTAR implementation. The CAB/CAP feedback, stakeholder interviews, and results of the pilot testing cycles will inform the final implementation toolkit used in the R33 phase.

Being tested
NavSTAR (Philly adaptation)
Keywords
patient navigation
Medical subject headings
Opioid-Related Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NavSTAR (Philly adaptation)Behavioural

    Patient Navigation

Study groups in NCT06634277
Study groupRoleWhat they receive
NavSTARExperimentalNavSTAR is a Patient Navigation service model to reduce internal and external barriers to recommended service engagement. It includes motivational interventions in tandem with proactive barrier resolution, targeting areas of addiction, medical, self-care, and basic needs.
Receives: Behavioral: NavSTAR (Philly adaptation)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Opioid Agonist Treatment (OAT) initiation

    Post-discharge OAT initiation will be measured by self-report at follow-up, with verification through records where applicable (e.g., Community Behavioral Health system).

    Measured: 3 months

Secondary outcomes (10)
  1. Acceptability: Extent to which the intervention will be deemed acceptable by participants

    Acceptability will be measured by the Acceptability of Intervention Measures Scale.

    Measured: 3 months

  2. Appropriateness: Extent to which the intervention will be deemed appropriate by participants

    Appropriateness will be measured using the Intervention Appropriateness Measure scale

    Measured: 3 months

  3. Changes in Psychological distress from baseline to 3 months

    Kessler-6 Psychological Distress Scale (K6) will be used to assess how participants have been feeling (nervous, hopeless, restless, depressed, worthless, etc) during their last 30 days.

    Measured: Baseline to 3-month follow-up

  4. Opioid use (oral fluid)

    Proportion of participants with positive oral fluid drug testing for opioids.

    Measured: 3 months

  5. Changes in Social Support from Baseline to Follow-up

    Social support will be measured using the Social Support Scale to determine the extent to which services influenced social support.

    Measured: Baseline to 3 month follow-up

  6. Change in Recovery Capital from baseline to follow-up

    Recovery capital will be assessed using the BARC-10 scale.

    Measured: Baseline to 3 month follow-up

  7. Changes in Quality of Life from Baseline to Follow-up

    Quality of life will be measured via the WHOQOL-BREF instrument.

    Measured: Baseline to 3 month follow-up

  8. Self-reported days of opioid use in the past 30 days

    Self-reported days of non-medical opioid use in the past 30 days will be assessed at each interview.

    Measured: Baseline to 3 month follow-up

  9. Hospital Utilization

    Information on acute care hospital utilization (including Emergency Department visits and Inpatient Admissions) will be assessed using health records and self-report (in the event of inconsistency, objective data will dominate).

    Measured: 3 months

  10. Feasibility: Demonstrated ability to enroll participants in the intervention

    Feasibility will be measured by enrollment rate (Target 8 participants per month/per hospital), calculated as the number of eligible participants relative to the number screened. This is an implementation outcome measured in the aggregate (not patient-level)

    Measured: From enrollment until end of follow-up (10 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Oct 2024
  2. Study start9 Aug 2024
  3. Primary completion26 Jul 2025
  4. Study completion31 Aug 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Model description
Single group pilot study with sequential implementation in 4 hospitals
Masking
None (open label)
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06634277
Sponsor's protocol ID
R61DA059033
Other IDs
R61DA059033
Acronym
Philly NavSTAR
Status last verified
Jun 2025
First submitted
3 Feb 2024
Last updated
29 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Because this is a feasibility pilot to inform a subsequent study, there is no plan to share IPD for the feasibility pilot. Interested researchers can nonetheless contact the PIs to discuss data sharing.

Publications

  • Gryczynski J, Nordeck CD, Welsh C, Mitchell SG, O'Grady KE, Schwartz RP. Preventing Hospital Readmission for Patients With Comorbid Substance Use Disorder : A Randomized Trial. Ann Intern Med. 2021 Jul;174(7):899-909. doi: 10.7326/M20-5475. Epub 2021 Apr 6.

    PubMed 33819055

Questions about this trial

What is this clinical trial studying?

A study testing NavSTAR (Philly adaptation) in people with Opioid Use Disorder, run by Friends Research Institute, Inc. at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Opioid Agonist Treatment (OAT) initiation (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06634277, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in